Evidence map›Paper›PMID 38452116›Full record

ArticleJournal of medicinal chemistry2024

Structure-Activity Relationships of Natural and Semisynthetic Plecomacrolides Suggest Distinct Pathways for HIV-1 Immune Evasion and Vacuolar ATPase-Dependent Lysosomal Acidification.

Morgan McCauley, Matthew Huston, Alanna R Condren, Filipa Pereira, Joel Cline, Marianne Yaple-Maresh, Mark M Painter, Gretchen E Zimmerman, Andrew W Robertson, Nolan Carney and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Morgan McCauleyUniversity of Michigan, Life Sciences Institute, Ann Arbor, Michigan 48109, United States.
Matthew HustonUniversity of Michigan, Department of Internal Medicine, Ann Arbor, Michigan 48109, United States.
Alanna R CondrenUniversity of Michigan, Life Sciences Institute, Ann Arbor, Michigan 48109, United States.
Filipa PereiraUniversity of Michigan, Life Sciences Institute, Ann Arbor, Michigan 48109, United States.
Joel ClineUniversity of Michigan, Department of Internal Medicine, Ann Arbor, Michigan 48109, United States.
Marianne Yaple-MareshUniversity of Michigan, Department of Internal Medicine, Ann Arbor, Michigan 48109, United States.
Mark M PainterUniversity of Michigan, Graduate Program in Immunology, Ann Arbor, Michigan 48109, United States.
Gretchen E ZimmermanUniversity of Michigan, Department of Internal Medicine, Ann Arbor, Michigan 48109, United States.
Andrew W RobertsonUniversity of Michigan, Life Sciences Institute, Ann Arbor, Michigan 48109, United States.
Nolan CarneyUniversity of Michigan, Department of Chemistry, Ann Arbor, Michigan 48109, United States.
Christopher GoodallUniversity of Michigan, Department of Internal Medicine, Ann Arbor, Michigan 48109, United States.
Valeri TerryUniversity of Michigan, Department of Internal Medicine, Ann Arbor, Michigan 48109, United States.
Rolf MüllerHelmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken 66123, Germany.
David H ShermanUniversity of Michigan, Department of Microbiology & Immunology, Ann Arbor, Michigan 48109, United States.ORCID 0000-0001-8334-3647
Kathleen L CollinsUniversity of Michigan, Graduate Program in Immunology, Ann Arbor, Michigan 48109, United States.
University of Michigan · USHelmholtz Institute for Pharmaceutical Research Saarland · DE

Funding

Development of natural product inhibitors of Nef for clearance of HIV reservoirsR01AI148383 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L., SHERMAN, DAVID H · 2019 to 2023
$3.8M
NIAID NIH HHS R01 AI148383
6 · The paper itself

Abstract

The human immunodeficiency virus (HIV)-encoded accessory protein Nef enhances pathogenicity by reducing major histocompatibility complex I (MHC-I) cell surface expression, protecting HIV-infected cells from immune recognition. Nef-dependent downmodulation of MHC-I can be reversed by subnanomolar concentrations of concanamycin A (

Indexed as

HIV-1HIV InfectionsVacuolar Proton-Translocating ATPasesHumansHydrogen-Ion ConcentrationImmune EvasionLysosomesnef Gene Products, Human Immunodeficiency Virusnef Gene Products, Human Immunodeficiency VirusVacuolar Proton-Translocating ATPases

Identifiers

PMID38452116
PMCPMC10978252
OpenAlexW4392544380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.